Discussion
The U.S. Food and Drug Administration (FDA) has extended the review period for mitapivat as a potential treatment for sickle cell disease (SCD), with a decision now expected by Feb. 1, 2027. The delay follows the FDA’s request for additional information to determine whether a Risk Evaluation and…